IMUX Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Benzinga - Mentions: IBIO ENGN IMCC VREX ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

10 days ago - By: Immunic, Inc.

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

25 days ago - By: Immunic, Inc.

Immunic to Participate in Industry and Investor Conferences in November

2 months ago - By: Immunic, Inc.

Immunic to Participate in Scientific and Investor Conferences in October

2 months ago - By: Benzinga - Mentions: EA MLTX ANRO

This Electronic Arts Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

4 months ago - By: The Motley Fool

Immunic (IMUX) Q2 Loss Widens 25%

5 months ago - By: Stocktwits

Immunic to Participate in Scientific and Industry Conferences in May

5 months ago - By: Stocktwits

Immunic, Inc. Announces Proposed Public Offering

2 months ago - By: Immunic, Inc.

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

2 months ago - By: Immunic, Inc.

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

3 months ago - By: Immunic, Inc.

Immunic to Participate in Investor and Scientific Conferences in September

4 months ago - By: Immunic, Inc.

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

5 months ago - By: Stocktwits

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

5 months ago - By: Stocktwits

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

5 months ago - By: Stocktwits - Mentions: UBS

Immunic to Participate in Investor, Scientific and Industry Conferences in June

5 months ago - By: Stocktwits - Mentions: IMU

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

6 months ago - By: Immunic, Inc.

Immunic, Inc. Announces Proposed Public Offering

5 months ago - By: Stocktwits

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

5 months ago - By: Stocktwits

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

5 months ago - By: Immunic, Inc.

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

6 months ago - By: Immunic, Inc.

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

6 months ago - By: Immunic, Inc.

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

6 months ago - By: Immunic, Inc.

Immunic to Participate in Investor, Scientific and Industry Conferences in June

6 months ago - By: Immunic, Inc.

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

7 months ago - By: Immunic, Inc.

Immunic to Participate in Scientific and Industry Conferences in May

7 months ago - By: Immunic, Inc.

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

8 months ago - By: Immunic, Inc.

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

8 months ago - By: Stocktwits - Mentions: VTI VXF

Immunic Stock Draws Investor Attention On $5.1M Registered Direct Offering: Retail’s On Wait-And-Watch Mode

8 months ago - By: Immunic, Inc.

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

8 months ago - By: Immunic, Inc.

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

9 months ago - By: Immunic, Inc.

IMMUNIC INC (IMUX) Stock News

IMUX Latest News, Press Relases and Analysis

12 Health Care Stocks Moving In Tuesday's After-Market Session

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Immunic to Participate in Industry and Investor Conferences in November

Immunic to Participate in Scientific and Investor Conferences in October

This Electronic Arts Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Immunic (IMUX) Q2 Loss Widens 25%

Immunic to Participate in Scientific and Industry Conferences in May

Immunic, Inc. Announces Proposed Public Offering

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Immunic to Participate in Investor and Scientific Conferences in September

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

Immunic to Participate in Investor, Scientific and Industry Conferences in June

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Immunic, Inc. Announces Proposed Public Offering

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Immunic to Participate in Investor, Scientific and Industry Conferences in June

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

Immunic to Participate in Scientific and Industry Conferences in May

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic Stock Draws Investor Attention On $5.1M Registered Direct Offering: Retail’s On Wait-And-Watch Mode

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Immunic to Participate in Scientific and Investor Conferences in March